Modus Therapeutics, a company focused on innovative treatments for patients with sickle cell disease (SCD), announced the appointment of Professor Thomas Knittel as Chief Medical Officer.
Professor Knittel has more than 10 years of clinical experience in Internal Medicine and more than 15 years of experience in research and development, medical affairs and marketing management in the pharmaceutical/ biotech industry.
Modus Therapeutics’ lead drug candidate sevuparin is currently in a Phase II clinical trial in patients with SCD.
Before joining Modus Therapeutics he worked for Prima Biomed, Berlin as Executive VP Medical & Scientific Development (2016-2017) and has been acting as CMO since 2012 for InDex Pharmaceuticals, Stockholm.
Formerly Professor Knittel held positions as Business Unit Director at Novo Nordisk for Central Europe (2010-2014), as General Manager Pharmaceuticals at Harlan Laboratories (2011) and as VP.
Professor Knittel has a medical degree with a specialist training in Internal Medicine and Gastroenterology and holds an associate professorship at the University Clinic Goettingen, Germany. Furthermore, Professor Knittel earned an MBA from the executive programme of Kellogg School of Management at Northwestern University, US.
Ellen K. Donnelly, Chief Executive of Modus Therapeutics, said: “We are very pleased to welcome Professor Knittell as our new CMO. He joins at an exciting time for the Company as we continue patient recruitment in our Phase II clinical study with sevuparin for SCD, which we expect to read out in 2018.”
Professor Knittell continued: “I am pleased to be joining Modus and I look forward to contributing to the Company’s success as it looks to generate the first clinical data evaluating the benefits that sevuparin, an extremely interesting novel drug candidate, is able to deliver to patients with SCD.”
He formally took up his appointment on mid-August 2017.
